3.68
0.35 (10.51%)
| Previous Close | 3.33 |
| Open | 3.35 |
| Volume | 7,909,204 |
| Avg. Volume (3M) | 5,007,691 |
| Market Cap | 1,098,424,832 |
| Price / Sales | 43.61 |
| Price / Book | 0.990 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -1,479.57% |
| Diluted EPS (TTM) | -0.560 |
| Quarterly Revenue Growth (YOY) | -57.50% |
| Total Debt/Equity (MRQ) | 6.63% |
| Current Ratio (MRQ) | 10.15 |
| Operating Cash Flow (TTM) | -78.40 M |
| Levered Free Cash Flow (TTM) | -189.06 M |
| Return on Assets (TTM) | -12.94% |
| Return on Equity (TTM) | -15.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | AbCellera Biologics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.97% |
| % Held by Institutions | 44.69% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Guardian Capital Advisors Lp | 30 Sep 2024 | 1,786,414 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Truist Securities, 171.74%) | Buy |
| Median | 7.50 (103.80%) | |
| Low | 5.00 (Keybanc, 35.87%) | Buy |
| Average | 7.50 (103.80%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 16 May 2025 | 10.00 (171.74%) | Buy | 2.03 |
| Keybanc | 16 Apr 2025 | 5.00 (35.87%) | Buy | 2.39 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |